Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Alzheimer Disease 18 Clear all
Completed No phase listed Observational

F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)

NCT02414282
View directory record Official record
Conditions
Alzheimer Disease, Progressive Posterior Cortical Dysfunction (PPCD)
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jul 23, 2026, 8:09 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

NCT04100889
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Late-Onset, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease Focal
Interventions
No Intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT00103649
View directory record Official record
Conditions
Alzheimer Disease
Interventions
xaliproden (SR57746A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Tau Screening Study in Subjects With Early Symptomatic AD

NCT03467477
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
9
States / cities
Irvine, California • Delray Beach, Florida • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking

NCT03919669
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
All Subjects
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation

NCT03901092
View directory record Official record
Conditions
Alzheimer Disease
Interventions
flortaucipir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease

NCT00566397
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04494700, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
62
States / cities
Phoenix, Arizona • Sun City, Arizona • Irvine, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT00104013
View directory record Official record
Conditions
Alzheimer Disease
Interventions
xaliproden (SR57746A)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
1,455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
32
States / cities
Mesa, Arizona • Peoria, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Tau Screening Study in Patients With Early Symptomatic AD

NCT03322462
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years to 85 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
San Diego, California • Santa Ana, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Jul 23, 2026, 8:09 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil

NCT01712074
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-05212377 (SAM-760), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
40
States / cities
Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

NCT01565343
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
New Haven, Connecticut • Hallandale, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

NCT01565291
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • North East, Maryland • Long Branch, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Flortaucipir F 18

NCT02278367
View directory record Official record
Conditions
Alzheimer's Disease, Traumatic Brain Injury, Depression
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

NCT00857415
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

NCT01447719
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 23, 2026, 8:09 AM EDT
Recruiting No phase listed Observational

F 18 T807 Tau PET Imaging of Alzheimer's Disease

NCT02414347
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jul 23, 2026, 8:09 AM EDT
Enrolling by invitation No phase listed Observational

F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)

NCT02414178
View directory record Official record
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

NCT00855868
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18, [11C]-PIB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Jul 23, 2026, 8:09 AM EDT
Active, not recruiting Not applicable Interventional

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)

NCT05637801
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer Disease 9, Alzheimer Disease 4, Alzheimer Disease 7, Alzheimer Disease 17, Alzheimer's Dementia Late Onset, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 8, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 18, Alzheimer Disease 19, Dementia, Dementia Alzheimers, Dementia, Mild, Dementia of Alzheimer Type, Dementia Moderate, Dementia Senile, Mild Cognitive Impairment, Mild Dementia, MCI, Cognitive Impairment, Cognitive Decline, Cognitive Impairment, Mild
Interventions
Spectris™ AD - Active, Spectris™ AD - Sham
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
68
States / cities
Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 23, 2026, 8:09 AM EDT
Active, not recruiting Phase 3 Interventional

A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

NCT06709014
View directory record Official record
Conditions
Early Alzheimers Disease
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
78
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 8:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

NCT03279523
View directory record Official record
Conditions
Alzheimer Disease, HIV
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects

NCT01265394
View directory record Official record
Conditions
Healthy
Interventions
[18F] Flutemetamol
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 40 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Healthy Volunteers

NCT01564706
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Jenkintown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2012 · Synced Jul 23, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease

NCT01689233
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TRx0237 200 mg/day, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 89 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
58
States / cities
Phoenix, Arizona • Bellflower, California • Costa Mesa, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 23, 2026, 8:09 AM EDT